Sutro Biopharma, Inc. (STRO) Stock Price & Analysis
Sutro Biopharma, Inc. (STRO) fell 2.29% to USD 20.07 as of September 8, 2026 at 07:34 UTC, according to Nexqual real-time market data.
STRO last closed at USD 20.07; the session ranged USD 19.86–20.43 on volume of 124,764 shares. Market capitalization is —, with a 52-week range of USD 7.15–43.85 (NGM). Source: Nexqual, September 8, 2026 at 07:34 UTC.
Key Statistics (as of September 8, 2026 at 07:34 UTC)
| Price | USD 20.07 |
|---|---|
| Change | ▼ 2.29% (down) |
| Previous Close | USD 20.07 |
| Open | USD 20.07 |
| Day Range | USD 19.86 – 20.43 |
| 52-Week Range | USD 7.15 – 43.85 |
| Volume | 124,764 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (STRO)
Nexqual's technical model rates STRO "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.13 (neutral) |
| vs SMA50 | Below (USD 24.59) |
| MACD | -1.16 (negative) |
From Sutro Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Through December 31, 2025, we have received an aggregate of approximately $1.016 billion in payments from all of our collaborations, which includes approximately $79 million in investments in our stock.
- Our proprietary technology is key to our ability to define the best number and positions of non-natural amino acids for conjugation based on: conjugation efficiency; functional activity/pharmacological properties; and pharmacokinetics and safety.
- Through December 31, 2025, all of our collaborations have provided us with an aggregate of approximately $1.016 billion in payments, which includes approximately $79 million in investments in our stock.
- Overview We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF ® , and our site-specific conjugation platform, XpressCF+ ® .
Partnerships
- In 2024, we entered into an Exclusive License Agreement with Ipsen granting Ipsen worldwide rights to develop and commercialize STRO-003.
- To maximize the value of our XpressCF ® and XpressCF+ ® platform technology, we have historically entered into multitarget, product-focused collaborations with leaders in the field of oncology, including our iADC collaboration with Astellas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.81 | ▼ 2.26% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.01 | ▼ 3.37% |
| SRRK | Scholar Rock Holding Corporatio | USD 55.33 | ▼ 1.37% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 3.99 | ▲ 5.84% |
| REPL | Replimune Group, Inc. | USD 15.04 | ▼ 5.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:34 UTC. This page is informational and not investment advice.